SpeedWeed

SEPTEMBER 4, 2021

The DEA published a new document in the Federal Register on September 2 requesting an increase in production for certain Schedule I and Schedule II substances so that it can initiate more research studies. . DEA firmly believes in supporting regulated research of schedule I controlled substances. Some states in the U.S.

DEA 52

DEA Research and Development Clinical Trials Extraction 52

Cannabis Law Report

OCTOBER 4, 2021

One of the known beneficial uses of psilocybin is as a palliative care tool for patients with advanced illness who suffer from anxiety and/or depression. A multitude of recent clinical trials shows the clear promise of psilocybin for this population suffering from these debilitating conditions.

Therapy 52

Therapy Patients Law Clinical Trials 52

Cannabis Law Report

FEBRUARY 10, 2022

Court of Appeals for the Ninth Circuit dismissed a petition for review of a Drug Enforcement Administration (DEA) response to an attorney’s letter seeking advice and guidance on how a physician could administer psilocybin to a terminally ill patient without incurring liability under the Controlled Substances Act (CSA). The RTT Act.

DEA 52

DEA Clinical Trials Policy Research and Development 52

Cannabis Law Report

MAY 31, 2022

The first path, that of traditional medicine, currently offers patients limited options. The only psychedelic drug that is approved (outside of clinical trials) for psychiatric use—as opposed to anesthesia—through the traditional medical system is Ketamine. 2022 Active FDA Clinical Trials and State-Regulated Systems.

Clinical Trials 52

Clinical Trials Legalization Therapy Decriminalization 52

Veriheal

APRIL 11, 2022

You don’t take that opium poppy and ask a patient to rub it on their lip for morphine. We know that the plant has powerful potential medical effects, but it clearly needs more refinement, more research and more data,” stated Groff, who envisions a future where patients can easily access ailment-targeted cannabis meds.

Pharmaceutical 104

Pharmaceutical Research and Development DEA Clinical Trials 104

Cannabis Law Report

APRIL 21, 2022

The availability of larger quantities of cGMP-compliant MDMA will facilitate ongoing clinical trials and provide for future therapeutic use following anticipated regulatory approvals. Publication of this process establishes “prior art,” contributing to MAPS’ patient access strategy by making intellectual property public .

Clinical Trials 52

Clinical Trials Research and Development Therapy Media 52

Cannabis Law Report

MAY 29, 2022

8] Spravato is derived from ketamine and categorized by DEA as a Schedule III controlled substance. To mitigate safety risks, FDA implemented a Risk Evaluation and Mitigation Strategy (REMS) with elements to assure safe use (ETASU) whereby patients self-administer the spray in their healthcare provider’s office under medical supervision.

Research and Development 52

Research and Development DEA Clinical Trials Therapy 52

SpeedWeed

AUGUST 11, 2021

This will be the second clinical trial to give cannabis medicine or placebos to participating military veterans, and according to the Chief Science Officer of the MAPS Public Benefit Corporation, Berra Yazar-Klosinki, PhD, the first trial was a great success. “We MAPS Makes History. The study was funded with $2.2

Clinical Trials 52

Clinical Trials Research and Development Pharmaceutical DEA 52

SpeedWeed

JULY 23, 2021

When you’re talking about wanting to do an actual clinical trial, you need a diversity of people that participate and one state just does not have the diversity of people that are required,” Towle said. We will have 30 patients in the first study with multiple forms of dementia,” CEO Albert Gutierrez explained.

Clinical Trials 52

Clinical Trials Research and Development DEA Cannabinoids 52

MedicalJane

JUNE 29, 2018

The new drug is indicated for the treatment of seizures associated with two rare and severe forms of epilepsy, Lennox-Gastaut syndrome and Dravet syndrome, in patients two years of age and older. It is also the first FDA approval of a drug for the treatment of patients with Dravet syndrome. Epidiolex contains less than 0.1

Clinical Trials 53

Clinical Trials CBD DEA Research and Development 53

Cannabis Law Report

JULY 9, 2021

Patients would participate in therapy sessions to prepare for the use of psychedelics, after which the substances would be administered under the guidance and supervision of trained medical professionals. See Usona Institute, A Study of Psilocybin for Major Depressive Disorder (MDD) , Clinical Trial ID NCT03866174, available at [link].

Law 105

Law Therapy Clinical Trials Research and Development 105

CannaMD

AUGUST 8, 2020

Drugs, substances, and certain chemicals used to make drugs are classified into five categories (known as schedules ) depending on the Department of Drug Enforcement Agency (DEA)’s definition of the drug’s acceptable medical use and abuse/dependency potential. ”, our first instinct is to remain patients that CBD is CBD.

CBD 100

CBD DEA Research and Development Hemp 100

The Cannigma

MAY 1, 2023

2 3 As clinical trials around the world proceeded in the late 1960s and 1970s, patients began reporting difficulty tolerating ketamine’s unpleasant hallucinogenic and dissociative properties. Ketamine was approved by the FDA in 1970 and was immediately put to use as an important tool for war medics in the Vietnam War.

Blood Pressure 80

Blood Pressure Chronic Pain Research and Development Clinical Trials 80

Veriheal

AUGUST 31, 2020

Essay Summary: Nishtha wants to further research into THC treatment for patients suffering from neurodegenerative diseases like Alzheimer’s and epilepsy , both of which cause neuron death. Program between St. Bonaventure University and George Washington University School of Medicine. .

Research and Development 117

Research and Development Education Agriculture Patients 117

Cannabis Law Report

AUGUST 18, 2022

Psychedelics present a new potential path to relief for patients who continue to struggle with mental health conditions despite conventional therapies,” he added. Study and development of these treatments remain challenging as psilocybin, MDMA, DMT and LSD are all listed as DEA Schedule I drugs. However, change appears imminent.

Therapy 52

Therapy Research and Development Pharmaceutical Treatment 52

Cannabis Law Report

FEBRUARY 28, 2022

Clinical trials are producing promising results, creating enthusiasm for commercializing and patenting psychedelics. 1025, 1026 (2021) (reporting significant improvement of PTSD symptoms following treatment with MDMA in clinical trial); see also Alec J. Mitchell et al., Divito & Robert F. 15 × 15. 16 × 16.

Research and Development 52

Research and Development Therapy Law Clinical Trials 52

SpeedWeed

MARCH 18, 2021

Preliminary results from a long-awaited study indicate that cannabis appears to be a safe and well-tolerated treatment for patients managing post-traumatic stress disorder (PTSD), although researchers did not find strong signals of effectiveness. for the production of cannabis used in federally-regulated clinical trials.

Clinical Trials 40

Clinical Trials THC Strains Cannabis 40

Weedistry

MARCH 7, 2019

A team of Spanish scientists led by Manuel Guzman conducted the first clinical trial assessing the antitumoral action of THC on human beings. Guzman administered pure THC via a catheter into the tumors of nine hospitalized patients with glioblastoma, who had failed to respond to standard brain-cancer therapies.

THC 40

THC CBD Clinical Trials Research and Development 40

Veriheal

JUNE 29, 2021

This Act permits individuals that have been diagnosed with life-threatening conditions or diseases that have exhausted all other approved treatment and therapeutic options that are also unable to participate in clinical trials the ability to access certain treatments that would otherwise be unapproved for access. A Push by Patients.

Therapy 59

Therapy DEA Patients Clinical Trials 59

SpeedWeed

MARCH 5, 2021

One, they have been determined by the US Food and Drug Administration to be clinically safe and effective treatments for a specific medical condition. Two, they are federally classified by DEA and HHS as Schedule II, III, IV or V substances. Rescheduling cannabis will not necessarily facilitate clinical research.

Business 52

Business Policy Clinical Trials Research and Development 52

Cannabis Law Report

APRIL 1, 2019

It aims to turn the plants’ chemical compounds into 2,500 5-milliliter bottles – the size of a teaspoon – of cannabis oil and sublingual drops for clinical trials among volunteer patients as early as July. It remains to be seen whether the Drug Enforcement Authority, or DEA, will designate cannabis zones for these farmers.

Research and Development 40

Research and Development Pharmaceutical Clinical Trials DEA 40

SpeedWeed

MARCH 28, 2021

CANNABIS CULTURE – The results are now in after the first-ever legal clinical trial into the use of cannabis to treat PTSD, but did the DEA’s rules taint the outcome? That’s what most providers are worried about when their patients with PTSD decide to try cannabis.”.

Clinical Trials 52

Clinical Trials DEA Treatment THC 52

Canna Law Blog

MAY 7, 2020

What you may not know is that the federal government actually has its own stash of cannabis for limited patient distribution and limited research purposes that it houses at the University of Mississippi (a/k/a) Ole Miss in Oxford, Mississippi. for various studies, including FDA-approved clinical trials.

DEA 71

DEA Research and Development Cultivation Supply Chain 71

Cannabis Law Report

JUNE 4, 2021

He practiced as a British Physiotherapist for over fifteen years, running clinics that specialized in integrative pain management and injury rehabilitation, treating over 40,000 patients. His first-hand experience with therapeutic hemp oil products as nutritional supplements led him to Medical Marijuana Inc.

Research and Development 105

Research and Development Seed-To-Sale Cannabinoids THC 105

Cannabis Law Report

APRIL 13, 2022

Complementary businesses combine to create a preeminent North American platform with operations spanning 13 wellness clinics, four research sites and one bioanalytical laboratory. Hosting clinical trials for MDMA ( MAPS Public Benefit Corporation), psilocybin (the Usona Institute), LSD (MindMed) and ketamine (the University of Utah ).

Clinical Trials 52

Clinical Trials Research and Development Therapy Treatment 52

Canna Law Blog

MARCH 4, 2020

Similar to ketamine, psilocybin has shown great promise in clinical trials for helping to effectively treat depression and PTSD (and we’ve written about psilocybin several times on this blog, including here and here ). Recently, the decriminalization of psilocybin (by various cities) has been in the news as an emerging medicine.

Therapy 89

Therapy Legalization Chronic Pain DEA 89

Veriheal

DECEMBER 21, 2022

The Drug Enforcement Administration (DEA) is now mandated to approve applications to be manufacturers of marijuana-derived, FDA-approved drugs under the bill. Every year more states legalize, more research studies and clinical trials take place, and more peer-reviewed articles are published in support of legal cannabis access. .

Clinical Trials 98

Clinical Trials Marijuana Decriminalization History 98

Cannabis Law Report

APRIL 8, 2022

This year, we are completing the second Phase 3 clinical trial of MDMA-assisted therapy for PTSD , the final stage prior to requesting FDA approval for a new prescription treatment to help heal trauma. Later that year, Doblin sued the DEA for the first time. Rick Doblin, Ph.D., and Michael Mithoefer, M.D., Lyle Craker, Ph.D.,

Clinical Trials 52

Clinical Trials Therapy Research and Development DEA 52

CannaMD

NOVEMBER 15, 2020

His findings are sure to alarm medical cannabis professionals and patients alike. Drug Enforcement Agency (DEA) announced that it will evaluate 37 additional grower applications. One such rule requires that all growers turn over all marijuana and by-products to the DEA shortly after harvest. Funding of Marijuana Research.

DEA 105

DEA Clinical Trials Cannabinoids Treatment 105

Canna Law Blog

MARCH 4, 2020

Similar to ketamine, psilocybin has shown great promise in clinical trials for helping to effectively treat depression and PTSD (and we’ve written about psilocybin several times on this blog, including here and here ). Recently, the decriminalization of psilocybin (by various cities) has been in the news as an emerging medicine.

Legalization 52

Legalization Therapy Chronic Pain DEA 52

The Cannigma

MAY 6, 2021

The Drug Enforcement Administration (DEA) recently issued a clarification on the matter, stating that “All synthetically derived tetrahydrocannabinols remain schedule 1 controlled substances”. The only clinical trial on delta-8-THC involving humans was done on children in Israel in 1995. Delta-8-THC research.

THC 145

THC Cannabinoids Concentrates Hemp 145

Cannabis Law Report

MARCH 21, 2019

Although the DEA refuses to remove marijuana from the schedule 1 list, the Farm Bill is considered to be the most important victory in the history of U.S. Georgia only allows patients diagnosed with cancer, ALS, seizures, and other serious medical conditions to legally possess CBD. Texas allows the use of CBD for epileptic patients.

State Laws 55

State Laws Law CBD Legalization 55

Cannabis Law Report

JULY 12, 2019

Recent studies on the effectiveness of cannabidiol in the rare seizure disorders Dravet Syndrome and Lennox-Gastaut syndrome have prompted a biopharmaceutical company to perform clinical trials of its own to bring a cannabidiol based drug to the American market through the process of FDA approval. No hepatic side effects were noted.

Extraction 73

Extraction Pharmaceutical CBD Epilepsy 73

SpeedWeed

DECEMBER 28, 2018

Bringing pharmaceutical CBD to market will make it available to patients in every state (with a doctor’s prescription), allow it to be covered by health insurance, and guarantee a product that’s produced to high standards. Bummer: Patients Are Still Struggling for Cannabis Access. RELATED STORY. RELATED STORY.

Pharmaceutical 40

Pharmaceutical Research and Development Legalization CBD 40

NORML

SEPTEMBER 20, 2019

We also spoke with her attorneys, who explained why they believed the DEA broke the law by holding up long-promised medical marijuana research licenses. Essentially, the federal government has monopolized cannabis research, and ElSohly’s product, according to some scientists who’ve seen it, is unsuitable for clinical trials.

DEA 224

DEA Research and Development Clinical Trials Patients 224